Lymph-node-negative oestrogen-receptor-positive breast cancer

Lancet

Volumn 364, Issue 9437, 2004, Pages 820-821

  Pansegrau, Gary K ^a   Gelmon, Karen A ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; HEART DISEASE; HUMAN; LYMPH NODE; NOTE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; BREAST TUMOR; FEMALE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; RECEPTORS, ESTROGEN; SURVIVAL RATE; TAMOXIFEN;

EID: 4544242411     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16994-8     Document Type: Note

References (10)

1. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 21:2003;976-983
2. Martin M, Pienkowski T, Mackey J, et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001; 55 months follow-up. San Antonio Breast Cancer Symposium, San Antonio, Texas, 2003: abstr 43.
3. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol. 21:2003;1431-1439
4. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 294:1976;405-410
5. Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the NSABP B-16. J Clin Oncol. 8:1990;1005
6. Chia SK, Speers CH, Bryce CJ, et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol. 22:2004;1630-1637
7. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 9:2003;923-930
8. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - results of the ATAC trial efficacy and safety update analyses. Cancer. 98:2003;1802-1810
9. Coomes RC, Hall E, Gibson LJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 350:2004;1081-1092
10. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 349:2003;1793-1802